Recent advances in pain management

Priyadarsini Baskaran; Venkatraman Karthikeayan; Anusha Natarajan

doi:10.18203/2319-2003.ijbcp20205553

Authors

Priyadarsini Baskaran Medical Monitor, Clinirx CRO, Chennai, Tamil Nadu, India
Venkatraman Karthikeayan Consultant Neuro-Immunologist, Global Hospitals, Chennai, Tamil Nadu, India
Anusha Natarajan Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20205553

Keywords:

Nociception, Pain therapy, Recent Advances in pain therapy

Abstract

Pain is one of the most common complaints for which patients approach physicians. In spite of this there is a huge unmet need for developing medications for pain that are safe and efficacious. Owing to the heterogeneity of clinical pain and complex pathophysiology, target identification for drug development is difficult. Preclinical models have also proven unreliable for the development of novel analgesics. Recent advances in understanding the physiology of nociception has enabled the development of novel analgesics including abuse deterrent opioids, drugs targeting several receptors, ion channels and enzymes. This review will attempt to cover the physiology of nociception focusing on the novel targets, the challenges in development of novel analgesics and give an overview of the recently developed drugs and those in the pipeline for the management of pain.

Metrics

Metrics Loading ...

References

Lee MC, Abrahams M. Pain and analgesics. Bennett PN, Brown MJ, Sharma P. In: Clinical pharmacology. 11th ed. Edinburgh: Elsevier. 2012;276-94.

Dinakar P. Principles of pain management. Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, editors. In: Bradley’s neurology in clinical practice. Seventh edition. London New York Oxford Philadelphia St Louis Sydney Toronto: Elsevier. 2016;720-41.

Flower RJ, Henderson G, Loke YK, MacEwan D, Rang HP. In: Rang and Dale's Pharmacology. 8th Edition. Elsevier Health Sciences. 2018;509-29.

Yekkirala A, Roberson D, Bean B. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017;16:545-64.

Chang DS, Raghavan R, Christiansen S, Cohen SP. Emerging targets in treating pain. Curr Opin Anaesthesiol. 2015;28:379-97.

Christoph A, Eerdekens M-H, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017;158:1813-24.

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03297294. Accessed on 07 April, 2020.

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03094195. Accessed on 07 April, 2020.

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02365636. Accessed on 07 April, 2020.

Yaksh T, Wallace M. Opioids, analgesia and pain management. Brunton L.L, Dandan RH, Knollmann KC, editors. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Thirteenth edition. New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto: McGraw Hill Education. 2018;355-86.

Abbadie C, McManus OB, Sun S-Y, Bugianesi RM, Dai G, Haedo RJ, et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010;334:545-55.

Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, et al. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg Med Chem Lett. 2013;23:1114-9.

Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02709486. Accessed on 07 April, 2020.

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee - Full Text View - ClinicalTrials.gov. Available from: https://clinical-trials.gov/ct2/show/NCT03691974. Accessed on 07 April, 2020.

Slatkin N, Zaki N, Wang S, Louie J, Sanga P, Kelly KM, et al. Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study. J Am Pain Soc. 2019;440-52.

Lane NE, Corr M. Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?. Nat Rev Rheumatol. 2017;13:76-8.